



## PRODUCT SUMMARY COMPOUNDED GS-441524 LIQUID ORAL SUSPENSION, TABLETS & CAPSULES

Clearpoint pharmacy is dedicated to maintaining high standards for product safety, consistency and quality.

- This product is compounded in Clearpoint Pharmacy's NAPRA-compliant facility, which is licensed by the Ontario College of Pharmacists and adheres to PCCA's highest compounding standards.
- The active pharmaceutical ingredients (APIs) for all our compounded products are sourced from GMP-licensed manufacturers
- Compounded products undergo third-party testing to ensure potency and quality
- Oral suspension, tablets and capsules are available in two flavours for added palatability

### FORMULATION

**Dosage Form:** Oral Suspension

**Strength:** 50mg/mL

**Available Volumes:** 30 mL and above qualifies for free shipping, but you may order any volume you prefer

**Available Flavours:** Fish or Chicken



**Dosage Form:** Tablets

**Strength:** 50 mg /Tablet (Quad-Scored)

**Available Pack Size:** 30 tablets and above qualifies for free shipping, but you may order any number of tablets you prefer

**Available Flavours:** Fish or Chicken





## FORMULATION, CONTINUED

**Dosage Form:** Capsules

**Strength:** 50mg/Capsule

**Available Pack Size:** 30 capsules and above qualifies for free shipping, but you may order any number of capsules you prefer

**Available Flavours:** Fish or Chicken



## CLINICAL USAGE AND EFFICACY

GS-441524 is an antiviral agent commonly used to treat Feline Infectious Peritonitis (FIP).<sup>1</sup> A nucleoside analogue, GS-441524 has been shown to be effective at halting viral replication by causing premature termination of viral RNA synthesis.<sup>2</sup>

FIP is considered to be 100% fatal without treatment.<sup>1</sup> Studies using GS-441524 to treat FIP have reported clinical resolution rates of 55.6-96%.<sup>1,3,4,5,6</sup> A large retrospective study of 307 cats treated with compounded GS-441524 and/or Remdesivir (of which GS-441524 is the active ingredient) showed a survival rate of 84.4% after 12 weeks of treatment.<sup>4</sup>

## DOSAGE

Because of the difficulties in penetrating the blood-brain and blood-eye barriers, cats presenting with ocular and neurological symptoms typically need higher dosages of GS-441524 compared to cats without neurological and ocular symptoms.<sup>10</sup>

Based on studies and clinical experience, International Cat Care has developed the following dosage guidelines:

Feline Infectious Peritonitis Clinical Manifestation	GS - 441524 Daily Oral Dose & Frequency
No ocular or neurological symptoms (With or without effusion)	15 mg/kg q24h (Or 7.5 mg/kg q12h)
FIP with ocular symptoms (with or without effusion)	15-20 mg/kg q24h (Or 7.5-10 mg/kg q12h)
FIP with neurological symptoms (with or without effusion)	10 mg/kg q12h (q24h dosing not recommended)

Dosage chart adapted from International Cat Care recommendations.<sup>7</sup>





Unpublished therapeutic dose monitoring (TDM) data suggests that dividing the daily dose and administering twice daily may yield more optimal drug serum concentrations.<sup>7</sup>

It is also important to note that pharmacokinetic studies as well as (unpublished) TDM data shows variance in the oral absorption of GS-441524<sup>7,8</sup> as well as in ocular and spinal fluid.<sup>2</sup> It is therefore considered necessary to increase dosages (in increments of 5-10 mg/kg/day) according to clinical response of the patient.<sup>7</sup> Note that cats being successfully treated for FIP may see significant weight gain during treatment, particularly growing kittens. It is very important to weigh cats weekly and adjust their dose for weight gain. Failure to do so appears to be a common cause for treatment failure.<sup>7</sup>

## TREATMENT DURATION

As of April 2025, nearly all FIP treatment data, published response rates and outcomes are for cats treated for 12 weeks. Recent research suggests that shorter treatment durations may be possible for some cats with effusive FIP whose clinical, haematological and biochemical parameters returned to normal within 28 days. A larger cohort study is currently underway. Until there is further data, a 12 week treatment duration remains recommended for most cats.

## ADMINISTRATION

No study has been published to examine the effects of food on oral GS-441524 absorption. Because the effect of taking this medication with food is unknown, it is recommended to give the medication with only a small treat (if necessary) on an empty stomach.<sup>7</sup>

## DRUG INTERACTION

To date, published research on GS-441524 has not identified any adverse drug interactions with GS-441524. It is recommended to minimize use of immunosuppressive drugs including corticosteroids in order to avoid inhibiting the immune response to FIP. NSAIDs rather than corticosteroids should be considered if appropriate if an anti-inflammatory agent is needed. However, there are recognized cases where corticosteroid use is necessary and appropriate, such as topical ophthalmic steroids for uveitis, severely neurologic cats, and cats with co-morbid IMHA.<sup>7</sup> If a corticosteroid is deemed necessary it should be used for the minimal duration and dosage required.





## ADVERSE EFFECTS

- Transient increases in ALT enzyme activity may be seen during FIP treatment. This will generally resolve without treatment and does not require use of hepatoprotectants.<sup>3,7</sup>
- Lymphocytosis and eosinophilia are sometimes reported.<sup>3,7</sup>
- There have been rare reports of uroliths composed of GS-441524. This may be related to usage of extremely high dosages of black market GS-441524 products. It is however prudent to take the precaution of increasing water intake for cats on high dosages of GS-441524 and investigate any urinary signs (including crystals or stones) that develop.<sup>7,9</sup>

## STORAGE

GS-441524 three oral forms, oral suspension, tablets and capsules should be stored at room temperature.

**For comprehensive details on GS-441524 antiviral therapy for Feline Infectious Peritonitis, including guidance on therapeutic monitoring, please consult the full Product Information Sheet available through our veterinary portal.**

## REFERENCES

1. Cosaro, E., Pires, J., Castillo, D., Murphy, B. G., & Reagan, K. L. (2023). Efficacy of Oral Remdesivir Compared to GS-441524 for Treatment of Cats with Naturally Occurring Effusive Feline Infectious Peritonitis: A Blinded, Non-Inferiority Study. *Viruses*, 15(8), 1680. <https://doi.org/10.3390/v15081680>
2. Murphy BG, Perron M, Murakami E, et al. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. *Vet Microbiol.* 2018;219:226-233. doi:10.1016/j.vetmic.2018.04.026
3. Coggins SJ, Norris JM, Malik R, et al. Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524. *J Vet Intern Med.* 2023; 37(5): 1772-1783. doi:10.1111/jvim.16803
4. Taylor SS, Coggins S, Barker EN, et al. Retrospective study and outcome of 307 cats with feline infectious peritonitis treated with legally sourced veterinary compounded preparations of remdesivir and GS-441524 (2020-2022). *J Feline Med Surg.* 2023;25(9):1098612X231194460. doi:10.1177/1098612X231194460
5. Green J, Syme H, Tayler S. Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524. *J Vet Intern Med.* 2023;37(5):1784-1793. doi:10.1111/jvim.16804
6. Zuzzi-Krebitz AM, Buchta K, Bergmann M, et al. Short Treatment of 42 Days with Oral GS-441524 Results in Equal Efficacy as the Recommended 84-Day Treatment in Cats Suffering from Feline Infectious Peritonitis with Effusion-A Prospective Randomized Controlled Study. *Viruses.* 2024;16(7):1144. Published 2024 Jul 16. doi:10.3390/v16071144





7. Taylor S, Tasker S, Gunn-Moore D, Barker E, Sorrell S. An update on treatment of FIP using antiviral drugs in 2024: growing experience but more to learn. International Cat Care. November 2024. Accessed April 21, 2025. <https://icatcare.org/resources/fip-vet-update-november-2024.pdf>
8. Cook S, Wittenburg L, Yan VC, Theil JH, Castillo D, Reagan KL, Williams S, Pham C-D, Li C, Muller FL, et al. An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats. Viruses. 2022; 14(11):2429. <https://doi.org/10.3390/v14112429>
9. Allinder M, Tynan B, Martin C, et al. Uroliths composed of antiviral compound GS-441524 in 2 cats undergoing treatment for feline infectious peritonitis. J Vet Intern Med. 2024;38(1):370-374. doi:10.1111/jvim.16954
10. Dickinson PJ, Bannasch M, Thomasy SM, et al. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. J Vet Intern Med. 2020;34(4):1587-1593. doi:10.1111/jvim.15780

